Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
10-QQuarterly report which provides a continuing view of a company's financial positionNov 15, 1999View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionSep 7, 1999View HTMLDownload DOCDownload PDFDownload XLS
S-8Securities offered to employees pursuant to employee benefit plansAug 9, 1999View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsJul 29, 1999View HTMLDownload DOCDownload PDF
424B4Form of prospectus disclosing information facts events covered in both forms 424B1 424B3Jul 26, 1999View HTMLDownload DOCDownload PDFDownload XLS
S-1/AAmended Registration statement for face-amount certificate companiesJul 22, 1999View HTMLDownload DOCDownload PDFDownload XLS
S-1/AAmended Registration statement for face-amount certificate companiesJul 21, 1999View HTMLDownload DOCDownload PDFDownload XLS
8-A12GRegistration of certain classes of securities 12(g) of the Securities Exchange ActJul 15, 1999View HTMLDownload DOCDownload PDFDownload XLS
S-1/AAmended Registration statement for face-amount certificate companiesJul 6, 1999View HTMLDownload DOCDownload PDFDownload XLS
S-1/AAmended Registration statement for face-amount certificate companiesJun 14, 1999View HTMLDownload DOCDownload PDFDownload XLS
S-1Registration statement for face-amount certificate companiesMay 4, 1999View HTMLDownload DOCDownload PDFDownload XLS

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information